SPDR S&P Biotech ETF
349 hedge funds and large institutions have $3.77B invested in SPDR S&P Biotech ETF in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 130 increasing their positions, 86 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
5% more capital invested
Capital invested by funds: $3.6B → $3.77B (+$170M)
6.17% less ownership
Funds ownership: 96.31% → 90.14% (-6.2%)
49% less call options, than puts
Call options by funds: $776M | Put options by funds: $1.51B
Holders
349
Holding in Top 10
18
Calls
$776M
Puts
$1.51B
Top Buyers
| 1 | +$98.9M | |
| 2 | +$40.2M | |
| 3 | +$39.9M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$23.4M |
Top Sellers
| 1 | -$159M | |
| 2 | -$121M | |
| 3 | -$86.2M | |
| 4 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$66.4M |
| 5 |
Goldman Sachs
New York
|
-$47.2M |